Asset Details
Do you wish to reserve the book?
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Do you wish to request the book?
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
2017
Overview
Among adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, treatment with the bispecific anti-CD19 and anti-CD3 monoclonal antibody blinatumomab resulted in longer overall survival and higher remission rates than did chemotherapy.
The prognosis for adults with newly diagnosed acute lymphoblastic leukemia (ALL) has improved over the past three decades. With the use of intensive chemotherapy regimens, complete remission rates are 85 to 90% and long-term survival rates are 30 to 50%.
1
–
4
Still, most adults with B-cell precursor ALL will have a relapse and will die from complications of resistant disease or associated treatment. Among adults with relapsed or refractory ALL, remission rates are 18 to 44% with the use of standard salvage chemotherapy, but the duration of remission is typically short.
5
–
10
A major goal in this population is to . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Antibodies, Bispecific - adverse effects
/ Antibodies, Bispecific - therapeutic use
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Female
/ Humans
/ Leukemia
/ Male
/ Patients
/ Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
/ Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality
/ Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy
/ Writers
